Effect of Trim21 knockdown on MAPK and ERBB signaling pathways
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA860116 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR20309118_1.fastq.gz | Fastqsanger.gz | |||
| SRR20309118_2.fastq.gz | Fastqsanger.gz | |||
| SRR20309119_1.fastq.gz | Fastqsanger.gz | |||
| SRR20309119_2.fastq.gz | Fastqsanger.gz | |||
| SRR20309120_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 36 |
Similar Datasets
Project description:To investigate Trim21 knockdown on the gene expression of downstream effectors of MAPK and ERBB pathways, we established HPAC cell lines with Trim21 knockdown.
2023-08-08 | GSE208568 | GEO
Project description:This study investigated the mechanisms underlying photosensitivity in patients with systemic lupus erythematosus (SLE), focusing on the role of type I interferons (IFNs) and TRIM21, an autoantigen in SLE. Through experiments on mice exposed to ultraviolet light B (UVB), we demonstrate that TRIM21 deficiency leads to exacerbated systemic inflammation and IFN-driven responses following UVB exposure, mimicking aspects of SLE pathology. Specifically, we observe enhanced expression of IFN-stimulated genes (ISGs), increased levels of inflammatory chemokines, and elevated IgG deposition in the skin of UVB-exposed Trim21-/- mice. Mechanistic investigations reveal that TRIM21 restrains IFN induction by regulating the STING pathway, impacting the stability of proteins involved in RNA/DNA sensing and IFN responses. These findings shed light on the protective role of TRIM21 against UVB-induced systemic disease in SLE, offering insights into its potential as a therapeutic target to mitigate disease flares and activity in SLE patients.
2025-08-13 | GSE265768 | GEO
Project description:Melanoma, originating from the malignant transformation of melanocytes, is the deadliest form of skin cancer. The incidence of primary cutaneous melanoma is increasing, with about 132,000 new cases annually. While early-stage melanoma can often be treated successfully with surgery, advanced melanoma remains challenging, necessitating new therapeutic targets. The MAPK pathway, particularly involving MEK and ERK, is critical in melanoma progression. PLEKHA4, a protein involved in cancer biology, has been identified as a key factor in melanoma cell proliferation and progression. Our study investigated the role of PLEKHA4 in regulating MAPK signaling and its impact on drug sensitivity in melanoma. Proteomic analysis, cell culture experiments, and various molecular techniques, including immunoblotting and quantitative proteomics, were employed to elucidate PLEKHA4’s function. Results indicates that PLEKHA4 is overexpressed in melanoma, promoting cell proliferation. PLEKHA4 knockdown induces apoptosis through the MAPK and cMyc pathway. enhances cMyc ubiquitination and degradation, suggesting a potential mechanism for its role in melanoma. These findings highlight PLEKHA4 as a significant player in melanoma progression and a potential target for therapeutic intervention.
2025-01-22 | PXD053608 | Pride
Project description:Bortezomib (bort) is an effective therapeutic agent for multiple myeloma (MM) patients; however, the majority of patients develop drug resistance. Autophagy, a highly conserved process that recycles cytosol or entire organelles via lysosomal activity, is essential for the survival, homeostasis and drug resistance in MM. Growing evidence has highlighted that E3 ligase tripartite motif-containing protein 21 (TRIM21) not only interacts with multiple autophagy regulators but also participates in drug resistance in various cancers. However, to date, the direct substrates and additional roles of TRIM21 in MM remain unexplored. In this study, we demonstrated that low TRIM21 expression is a factor for relapse in MM. TRIM21 knockdown (KD) made MM cells more resistant to bort, while TRIM21 overexpression (OE) resulted in increased MM sensitivity to bort. Proteomic and phospho-proteomic studies of TRIM21 KD MM cells showed that bort resistance was associated with increased oxidative stress and elevated pro-survival autophagy. Our results provided that TRIM21 KD MM cell lines induced pro-survival autophagy after bort treatment, and suppressing autophagy by 3-methyladenine treatment or by the short hairpin RNA of ATG5 restored bort sensitivity. Indeed, autophagy-related gene 5 (ATG5) expression was increased and decreased by TRIM21 KD and OE, respectively. TRIM21 affected autophagy by ubiquitinating ATG5 through K48 for proteasomal degradation. Importantly, we confirmed that TRIM21 could potentiate the anti-myeloma effect of bort through in vitro and in vivo experiments. Overall, our findings define the key role of TRIM21 in MM bort resistance and provide a foundation for a novel targeted therapeutic approaches.
2023-10-24 | PXD042004 | Pride
Project description:Loss of TRIM21 drives UVB-induced systemic inflammation by regulating DNA-sensing pathways
| PRJNA1104167 | ENA
Project description:Macrophage polarization followed by acute myocardial infarction (MI) is essential for the regulation of inflammation and scar formation. Tripartite motif-containing protein 21 (TRIM21), a member of E3 ubiquitin ligases, is a crucial mediator in the process of inflammation and heart failure. However, the potential roles of TRIM21 in modulating post-MI inflammation and macrophage polarization remain elusive. We detected that the levels of TRIM21 were significantly reduced in macrophages of WT mice after MI. In contrast, MI was ameliorated in TRIM21 knockout (TRIM21-/-) mice with improved cardiac remodeling, characterized by a marked decrease in mortality, increased wall thickness, and improved cardiac function in comparison with wild-type (WT) MI mice. Importantly, TRIM21 deficiency decreased the post-MI apoptosis and DNA damage in the hearts of mice, and the accumulation of M1 phenotype macrophages in infarcted hearts significantly decreased in TRIM21-/- mice compared with WT controls. Mechanistically, depletion of TRIM21 orchestrated the process of M1 macrophage polarization via a PI3K/Akt signaling pathway. Overall, these data reveal that TRIM21 drives the inflammatory response and cardiac remodeling after MI via stimulating M1 macrophage polarization through a PI3K/Akt signaling pathway.
2022-12-31 | GSE214696 | GEO
Project description:In order to better understand signaling events following receptor dimerization involving HER2, we have generated an experimental system in which ErbB dimerization can be controlled. We used gene expression microarrays to identify genes and pathways that are differentially activated by HER2 homodimers and HER2 containing heterodimers.
2011-05-13 | GSE22288 | GEO
Project description:To investigate the biological function Trim21 in the colon cancer, we compared the gene expression profiles of colon tumor tissues from Trim21 +/+ and Trim21 -/- mice treated with the carcinogen azoxymethane (AOM) and the proinflammatory agent dextran sulfate sodium (DSS).
2025-08-22 | GSE254960 | GEO
Project description:In order to better understand signaling events following receptor dimerization involving HER2, we have generated an experimental system in which ErbB dimerization can be controlled. We used gene expression microarrays to identify genes and pathways that are differentially activated by HER2 homodimers and HER2 containing heterodimers. MCF10A-HER2-FKBP-HA cells were treated with AP1510, TGFalpha or heregulin for 48 hrs prior to RNA harvest for array analysis.
2011-05-13 | E-GEOD-22288 | biostudies-arrayexpress
Project description:The present study comprehensively revealed the molecular characteristics in relation to OC and identified significantly distinct phosphorylated sites and phosphorylated proteins underlying the syndrome. The results here dissected regulatory elements (especially kinases) and pathways involved in cancer-related pathways including fructose & mannose metabolism, MAPK, ErbB, and ErbB signaling pathway. These findings may not only provide potential biomarkers and novel therapeutic targets for OC, but also bolstered our knowledge on the physiopathology of this syndrome.
2019-12-31 | PXD016183 |